Journal article · 2026 · Open access
Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study
The Lancet Oncology, 27(11), 1403–1419 · Published 26 October 2026 · DOI 10.1016/s1470-2045(26)00290-1
In brief
“Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study” is a 2026 journal article by Peter Borchmann and 30 co-authors, published in The Lancet Oncology. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY licence: the full text is free to read at The Lancet Oncology.
- Citations
- 0
- References
- 28
- Authors
- 31
Abstract
Background Anti-CD19 CAR T-cell therapy is the standard second-line treatment for patients with relapsed or refractory large B-cell lymphoma. However, there is no evidence from randomised controlled trials in patients ineligible for transplantation. To address this gap, we compared zamtocabtagene autoleucel (zamto-cel), a CAR T-cell therapy directed at CD20 and CD19, with rituximab–gemcitabine–oxaliplatin (R-GemOx) chemoimmunotherapy in patients ineligible for transplantation with relapsed or refractory large B-cell lymphoma. Methods DALY 2-EU is an open-label, multicentre, randomised, phase 2 trial conducted at 45 centres across 12 countries in Europe. Eligible patients were adults (aged ≥18 years) with second-line relapsed or refractory large B-cell lymphoma confirmed histologically who were ineligible for transplantation and had received first-line chemoimmunotherapy containing a combination of an anthracycline-based regimen and an anti-CD20 monoclonal antibody, with Eastern Cooperative Oncology Group performance status score of 2 or less. Patients were randomly assigned (1:1) to zamto-cel (single intravenous infusion of 2·5 × 10 6 fresh (ie, non-cryopreserved) CAR T-cells per kg, capped at 100 kg, produced in a closed automated system) or R-GemOx (rituximab [375 mg/m 2 intravenously on day 1], gemcitabine [1000 mg/m 2 intravenously on day 1 or 2], and oxaliplatin [100 mg/m 2 intravenously on day 1 or 2] administered for up to eight 14-day cycles). Randomisation was done with an interactive web response system and stratified by age, gender, lactate dehydrogenase, International Prognostic Index, histology, time to relapse after the start of first-line therapy, and country. The primary endpoint was event-free survival assessed by a masked independent review committee and compared all patients randomly assigned to the zamto-cel and R-GemOx groups using a one-sided log-rank test. Safety was assessed in all patients who received study treatment. This ongoing trial is registered with ClinicalTrials.gov (NCT04844866). Findings Between Oct 14, 2021, and Jul 16, 2024, 219 patients were screened and 160 were randomly assigned to zamto-cel (n=82) and R-GemOx (n=78). The median age was 74·0 years (IQR 70·5–77·0). Patients were predominantly male (100 [63%] of 160 were men and 60 [38%] women) and White (91 [57%]), with race not reported for 64 (40%). Median vein-to-vein time for zamto-cel was 15 days (IQR 15–16). With a median follow-up of 17·0 months (IQR 9·0–22·8), event-free survival was longer in the zamto-cel group than in the R-GemOx group (6·21 months [95% CI 3·84–13·77] vs 2·53 months [1·97–3·35]; HR 0·39 [95% CI 0·27–0·58]; p<0·0001). Grade 3 or higher treatment-emergent adverse events occurred in 63 (83%) of 76 with zamto-cel and in 65 (86%) of 76 with R-GemOx. The most common grade 3–4 adverse…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Borchmann, P., van Meerten, T., Iacoboni, G., Bories, P., Dreger, P., Mutsaers, P., Gopcsa, L., Edinger, M., Gergely, L., von Tresckow, B., Neumeister, P., Steiner, N., Jäger, U., Moreno, A. T., Griškevičius, L., Lemonnier, F., van Doesum, J. A., Kersten, M. J., Rudzki, J. D., . . . Vandenberghe, P. (2026). Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study. The Lancet Oncology, 27(11), 1403–1419. https://doi.org/10.1016/s1470-2045(26)00290-1
MLA 9
Borchmann, Peter, et al. “Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.” The Lancet Oncology, vol. 27, no. 11, 2026, pp. 1403–1419. https://doi.org/10.1016/s1470-2045(26)00290-1.
Chicago
Borchmann, Peter, Tom van Meerten, Gloria Iacoboni, Pierre Bories, Peter Dreger, Pim Mutsaers, László Gopcsa, et al. 2026. “Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.” The Lancet Oncology 27 (11): 1403–1419. https://doi.org/10.1016/s1470-2045(26)00290-1.
Harvard
Borchmann, P. et al. (2026) ‘Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study’, The Lancet Oncology, 27(11), pp. 1403–1419. doi:10.1016/s1470-2045(26)00290-1.
IEEE
P. Borchmann et al., “Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study,” The Lancet Oncology, vol. 27, no. 11, pp. 1403–1419, 2026, doi: 10.1016/s1470-2045(26)00290-1.
BibTeX
@article{borchmann2026zamtocabtagene,
title = {{Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study}},
author = {Borchmann, Peter and van Meerten, Tom and Iacoboni, Gloria and Bories, Pierre and Dreger, Peter and Mutsaers, Pim and Gopcsa, László and Edinger, Matthias and Gergely, Lajos and von Tresckow, Bastian and Neumeister, Peter and Steiner, Normann and Jäger, Ulrich and Moreno, Ana Triguero and Griškevičius, Laimonas and Lemonnier, François and van Doesum, Jaap A. and Kersten, Marie José and Rudzki, Jakob Daniel and Shah, Nirav N and Orentas, Rimas J. and Friedrichs, Birte and Miltenyi, Stefan and Overstijns, Toon and Bürger, Iris and Zadoyan, Gregor and Brillant, Corinne and Paul, Pamella and van Heteren, Pearl and Holtkamp, Silke and others},
journal = {The Lancet Oncology},
year = {2026},
volume = {27},
number = {11},
pages = {1403--1419},
doi = {10.1016/s1470-2045(26)00290-1},
url = {https://doi.org/10.1016/s1470-2045(26)00290-1}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- large B-cell lymphoma
- relapsed/refractory lymphoma
- second-line therapy
- transplant-ineligible patients
- event-free survival
- CAR T cell safety
- non-Hodgkin lymphoma
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Borchmann, P., van Meerten, T., Iacoboni, G., Bories, P., Dreger, P., Mutsaers, P., Gopcsa, L., Edinger, M., Gergely, L., von Tresckow, B., Neumeister, P., Steiner, N., Jäger, U., Moreno, A. T., Griškevičius, L., Lemonnier, F., van Doesum, J. A., Kersten, M. J., Rudzki, J. D., . . . Vandenberghe, P. (2026). Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study. The Lancet Oncology, 27(11), 1403–1419. https://doi.org/10.1016/s1470-2045(26)00290-1
How many times has this paper been cited?
0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at The Lancet Oncology: sign in and open the full text from this page.
Who wrote this paper?
Peter Borchmann, Tom van Meerten, Gloria Iacoboni, Pierre Bories, Peter Dreger, Pim Mutsaers, László Gopcsa, Matthias Edinger, Lajos Gergely, Bastian von Tresckow, Peter Neumeister, Normann Steiner and 19 more.
What is the DOI of this paper?
10.1016/s1470-2045(26)00290-1, permanently at https://doi.org/10.1016/s1470-2045(26)00290-1. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.